Most patients (69.2%) had advanced clinical stage (Binet stage C CLL or stage III/IV SLL) and at least one additional poor prognostic variable, including unmutated IGHV (56.0%), del(17p) or TP53 mutation (24.2%), and/or del(11q) (22%). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.